Cargando…
In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor
The concept of polypharmacology involves the interaction of drug molecules with multiple molecular targets. It provides a unique opportunity for the repurposing of already‐approved drugs to target key factors involved in human diseases. Herein, we used an in silico target prediction algorithm to inv...
Autores principales: | Ariey‐Bonnet, Jeremy, Carrasco, Kendall, Le Grand, Marion, Hoffer, Laurent, Betzi, Stéphane, Feracci, Mikael, Tsvetkov, Philipp, Devred, Francois, Collette, Yves, Morelli, Xavier, Ballester, Pedro, Pasquier, Eddy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718943/ https://www.ncbi.nlm.nih.gov/pubmed/33021050 http://dx.doi.org/10.1002/1878-0261.12810 |
Ejemplares similares
-
Predicting Synergism of Cancer Drug Combinations Using NCI-ALMANAC Data
por: Sidorov, Pavel, et al.
Publicado: (2019) -
Mebendazole elicits potent antimyeloma activity by inhibiting the USP5/c-Maf axis
por: Chen, Xue-han, et al.
Publicado: (2019) -
Pharmacological inhibition of syntenin PDZ2 domain impairs breast cancer cell activities and exosome loading with syndecan and EpCAM cargo
por: Leblanc, R., et al.
Publicado: (2020) -
Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma
por: Younis, Nancy S., et al.
Publicado: (2019) -
Treatment of echinococcosis: albendazole and mebendazole – what else?
por: Hemphill, Andrew, et al.
Publicado: (2014)